Lineage Cell Therapeutics Inc (LCTX)

AMEXHealth CareBiotechnologySnapshot 2026-10-23

$1.00+1.52%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Lineage Cell Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	12.14M
EPS	—	-0.004
Annual ending 2026-12-31
Revenue	—	15.16M
EPS	—	-0.059
Annual ending 2027-12-31
Revenue	—	19.7M
EPS	—	-0.097

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance therapeutic candidates and build cell therapy pipeline	A primary condition in Lineage Cell Therapeutics Inc's published investment case. The stated target is Sustain advancement of cell-based assets pipeline over next 12 months.	Improving	No meaningful progress or setbacks in key therapeutic programs	Qualitative: COR1 'Thew and Inject' plan mapped (Jul 2026) July 2026 news highlights COR1 'Thaw and Inject' plan and manufacturing strategy discussions, reinforcing pipeline advancement. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Pursue and maintain partnerships for cell-based assets	The company has partnerships with Roche and WDI to develop cell therapies.	Intact	Loss of key partnerships or no new deals in 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew modestly from $1.5M in 2025-Q1 to $1.7M in 2026-Q1, reflecting collaboration revenue from WDI. Management continues to pursue and maintain partnerships supporting cell-based assets, showing delivering progress. Delivery assessment Oct 24, 2026
Revenue grows from $1.7M in Q2 to at least $14.6M in 2026	A primary condition in Lineage Cell Therapeutics Inc's published investment case. The stated target is >= $14.6 million total revenue by 2026-12-31.	Intact	Revenue falls below $14 million in FY26	Revenue: $1.069M FY2026-Q2; GAAP. Published target: >= $14.6 million total revenue by 2026-12-31. Target period is not explicitly aligned with this observation. Source published Aug 6, 20261,069,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3792282c-fbc4-40bf-900a-5ce2f500edbf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-0.09 → Unavailable · observed estimates

FY2027 revenue$0.02B

$0.01B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.09	$10,350,000	5 / 5
2026-07-25	$-0.09	$10,350,000	5 / 5
2026-07-26	$-0.09	$10,350,000	5 / 5
2026-07-27	$-0.09	$10,350,000	5 / 5
2026-07-28	$-0.09	$10,350,000	5 / 5
2026-07-29	$-0.09	$10,350,000	5 / 5
2026-07-30	$-0.09	$18,142,860	5 / 7
2026-07-31	$-0.09	$10,350,000	5 / 5
2026-08-01	$-0.09	$10,350,000	5 / 5
2026-08-02	$-0.09	$18,142,860	5 / 7
2026-08-03	$-0.09	$18,142,860	5 / 7
2026-08-04	$-0.09	$18,142,860	5 / 7
2026-08-05	$-0.09	$18,142,860	5 / 7
2026-08-06	$-0.09	$18,142,860	5 / 7
2026-08-07	$-0.09	$10,350,000	5 / 5
2026-08-08	$-0.09	$10,350,000	5 / 5
2026-08-09	$-0.09	$18,142,860	5 / 7
2026-08-10	$-0.09	$18,142,860	5 / 7
2026-08-12	$-0.09	$10,350,000	5 / 5
2026-08-13	$-0.10	$19,640,170	5 / 6
2026-08-14	$-0.09	$10,350,000	5 / 5
2026-08-15	$-0.09	$10,350,000	5 / 5
2026-08-16	$-0.09	$10,350,000	5 / 5
2026-08-17	$-0.09	$10,350,000	5 / 5
2026-08-18	$-0.09	$10,350,000	5 / 5
2026-08-19	$-0.09	$10,350,000	5 / 5
2026-08-20	$-0.10	$8,658,200	5 / 5
2026-08-21	$-0.10	$8,658,200	5 / 5
2026-08-22	$-0.10	$8,658,200	5 / 5
2026-08-23	$-0.10	$8,658,200	5 / 5
2026-08-24	$-0.10	$8,658,200	5 / 5
2026-08-25	$-0.10	$8,658,200	5 / 5
2026-08-26	$-0.10	$8,658,200	5 / 5
2026-08-27	$-0.10	$8,658,200	5 / 5
2026-08-28	$-0.10	$8,658,200	5 / 5
2026-08-29	$-0.10	$8,658,200	5 / 5
2026-08-30	$-0.10	$8,658,200	5 / 5
2026-08-31	$-0.10	$8,658,200	5 / 5
2026-09-01	$-0.10	$8,658,200	5 / 5
2026-09-02	$-0.10	$8,658,200	5 / 5
2026-09-03	$-0.10	$8,658,200	5 / 5
2026-09-04	$-0.10	$8,658,200	5 / 5
2026-09-05	$-0.10	$8,658,200	5 / 5
2026-09-06	$-0.10	$8,658,200	5 / 5
2026-09-07	$-0.10	$8,658,200	5 / 5
2026-09-08	$-0.10	$8,658,200	5 / 5
2026-09-09	$-0.10	$8,658,200	5 / 5
2026-09-10	$-0.10	$8,658,200	5 / 5
2026-09-11	$-0.10	$8,658,200	5 / 5
2026-09-12	$-0.10	$8,658,200	5 / 5
2026-09-13	$-0.10	$8,658,200	5 / 5
2026-09-14	$-0.10	$8,658,200	5 / 5
2026-09-15	$-0.10	$8,658,200	5 / 5
2026-09-16	$-0.10	$8,658,200	5 / 5
2026-09-17	$-0.10	$8,658,200	5 / 5
2026-09-18	$-0.10	$8,658,200	5 / 5
2026-09-19	$-0.10	$8,658,200	5 / 5
2026-09-20	$-0.10	$8,658,200	5 / 5
2026-09-21	$-0.10	$8,658,200	5 / 5
2026-09-22	$-0.10	$8,658,200	5 / 5
2026-09-23	$-0.10	$8,658,200	5 / 5
2026-09-24	$-0.10	$8,658,200	5 / 5
2026-09-25	$-0.10	$8,658,200	5 / 5
2026-09-26	Unavailable	$19,698,500	4 / 5
2026-09-27	Unavailable	$19,698,500	4 / 5
2026-09-28	Unavailable	$19,698,500	4 / 5
2026-09-29	Unavailable	$19,698,500	4 / 5
2026-09-30	Unavailable	$19,698,500	4 / 5
2026-10-01	Unavailable	$19,698,500	4 / 5
2026-10-02	Unavailable	$19,698,500	4 / 5
2026-10-03	Unavailable	$19,698,500	4 / 5
2026-10-04	Unavailable	$19,698,500	4 / 5
2026-10-05	Unavailable	$19,698,500	4 / 5
2026-10-06	Unavailable	$19,698,500	4 / 5
2026-10-07	Unavailable	$19,698,500	4 / 5
2026-10-08	Unavailable	$19,698,500	4 / 5
2026-10-09	Unavailable	$19,698,500	4 / 5
2026-10-10	Unavailable	$19,698,500	4 / 5
2026-10-11	Unavailable	$19,698,500	4 / 5
2026-10-12	Unavailable	$19,698,500	4 / 5
2026-10-13	Unavailable	$19,698,500	4 / 5
2026-10-14	Unavailable	$19,698,500	4 / 5
2026-10-15	Unavailable	$19,698,500	4 / 5
2026-10-16	Unavailable	$19,698,500	4 / 5
2026-10-17	Unavailable	$19,698,500	4 / 5
2026-10-18	Unavailable	$19,698,500	4 / 5
2026-10-19	Unavailable	$19,698,500	4 / 5
2026-10-20	Unavailable	$19,698,500	4 / 5
2026-10-21	Unavailable	$19,698,500	4 / 5
2026-10-22	Unavailable	$19,698,500	4 / 5
2026-10-23	Unavailable	$19,698,500	4 / 5
2026-10-24	Unavailable	$19,698,500	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	6	1
2026-10-01	6	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Pursue and maintain partnerships for cell-based assetsQualitative condition
Revenue grows from $1.7M in Q2 to at least $14.6M in 2026Revenue: $1.069M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-53.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Lineage Cell Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, development-stage biotech thesis, not an established earnings compounder: the company is loss-making and recent financial performance is weak. Management is advancing therapeutic candidates and manufacturing initiatives, but the thesis remains on watch because results trail the industry cohort.

What's priced into Lineage Cell Therapeutics Inc

Valuation is stretched, with a durable premium versus peers and a modest expectations gap. The evidence points to valuation as the main fragility, rather than a combination of expensive valuation, weak fundamentals, and turbulent conditions; confidence in that assessment is low.

What the fundamentals likely do

Near term, revenue fell from $1.7 million in 2026-Q1 to $1.1 million in 2026-Q2 as collaboration revenue declined, while operating expenses decreased and management reported progress on its candidates and manufacturing work. The next results carry meaningful execution risk: a guidance cut or continued weak sector results could add pressure, while recent earnings events were mostly in line.

What Lineage Cell Therapeutics Inc hinges on

Over the multi-year view, the key question is whether OpRegen, COR1, and manufacturing initiatives advance enough to support future partnerships and development progress. Near term, guidance, collaboration revenue, and broader Healthcare sector results are important swing factors; the evidence does not establish their outcomes.